ABC | Volume 111, Nº3, Setembro 2018

Artigo Original Marino et al Adiponectina e VH-IVUS com as características da placa aterosclerótica Arq Bras Cardiol. 2018; 111(3):345-353 Agradecimentos Gostaríamos de agradecer ao seguintes cardiologistas intervencionistas e equipe técnica por sua contribuição para este estudo: Eric Duckers, MD, PhD; Willem van der Giessen, MD, PhD; Peter P.T. de Jaegere, MD, PhD; Jurgen M.R. Ligthart; Nicolas M.D.A. van Mieghem, MD, PhD; Carl Schultz, MD, PhD; Karen T. Witberg and Felix Zijlstra, MD, PhD. Contribuição dos autores Concepção e desenho da pesquisa: Akkerhuis M, Garcia‑Garcia HM, Serruys PW, Boersma E, Kardys I; Obtenção de dados: Buljubasic N, Cheng JM, Garcia‑Garcia HM, Regar E, Robert-Jan VG, Serruys PW, Kardys I; Análise e interpretação dos dados: Marino BCA, Buljubasic N, Akkerhuis M, Cheng JM, Garcia-Garcia HM, Regar E, Robert-Jan VG, Serruys PW, Boersma E, Kardys I; Análise estatística e Redação do manuscrito: Marino BCA; Obtenção de financiamento: Serruys PW, Boersma E, Kardys I; Revisão crítica do manuscrito quanto ao conteúdo intelectual importante: Buljubasic N, Akkerhuis M, Cheng JM, Garcia-Garcia HM, Regar E, Robert‑Jan VG, Serruys PW, Boersma E, Kardys I. Potencial conflito de interesses Declaro não haver conflito de interesses pertinentes. Fontes de financiamento O presente estudo foi parcialmente financiado pelo European Commission, Dutch Government e Netherlands Heart Foundation. Vinculação acadêmica Este artigo é parte de tese de Doutorado de Barbara C. A. Marino pela Universidade Federal de Minas Gerais. Aprovação ética e consentimento informado Este estudo foi aprovado pelo Comitê de Ética do Erasmus MC sob o número de protocolo NCT01789411. Todos os procedimentos envolvidos nesse estudo estão de acordo com a Declaração de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes incluídos no estudo. 1. NewbyDE. Triggering of acutemyocardial infarction: beyond the vulnerable plaque. Heart. 2010;96(15):1247-51. 2. Narula J, Garg P, Achenbach S, Motoyama S, Virmani R, Strauss HW. Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med. 2008;5 Suppl 2:S2-10. 3. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115-26. 4. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta. 2004;344(1-2):1-12. 5. Barseghian A, Gawande D, Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol. 2011;57(7):761-70. 6. Matsuzawa Y. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl. 2005;6(2):7-14. 7. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277(29):25863-6. 8. SzmitkoPE,TeohH,StewartDJ,VermaS.Adiponectinandcardiovasculardisease: stateoftheart?AmJPhysiolHeartCircPhysiol.2007;292(4):H1655-63. 9. SattarN,WannametheeG,SarwarN,TchernovaJ,CherryL,WallaceAM,etal. Adiponectinandcoronaryheartdisease:aprospectivestudyandmeta-analysis. Circulation.2006;114(7):623-9.Erratumin:Circulation.2007;115(10):e325. 10. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380(1-2):24-30. 11. deBoerSP,ChengJM,Garcia-GarciaHM,OemrawsinghRM,vanGeunsRJ,Regar E,etal.Relationofgeneticprofileandnovelcirculatingbiomarkerswithcoronary plaquephenotypeasdeterminedbyintravascularultrasound:rationaleanddesign oftheATHEROREMO-IVUSstudy.EuroIntervention.2014;10(8):953-60. 12. Cheng JM, Garcia-Garcia HM, de Boer SP, Kardys I, Heo JH, Akkerhuis KM, et al. In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Eur Heart J. 2014;35(10):639-47. 13. Garcia-GarciaHM, Mintz GS, Lerman A, VinceDG, MargolisMP, van Es GA, etal.Tissuecharacterisationusing intravascularradiofrequencydataanalysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention. 2009;5(2):177-89. 14. Nair A, Margolis MP, Kuban BD, Vince DG. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. EuroIntervention. 2007;3(1):113-20. 15. García-GarcíaHM, Mintz GS, Lerman A, VinceDG, MargolisMP, van Es GA, etal.Tissuecharacterisationusing intravascularradiofrequencydataanalysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention. 2009;5(2):177-89. 16. Rodriguez-Granillo GA, García-García HM, Mc Fadden EP, Valgimigli M, Aoki J, de Feyter P, et al. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol. 2005;46(11):2038-42. 17. Erhardt L, Herlitz J, Bossaert L, HalinenM, Keltai M, Koster R, et al; Task force on the management of chest pain .Task force on the management of chest pain. Eur Heart J. 2002;23(15):1153-76. 18. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST- segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054. 19. Van deWerf F, Bax J, BetriuA, Blomstrom-Lundqvist C, Crea F, Falk V, et al; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task ForceontheManagementofST-SegmentElevationAcuteMyocardialInfarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909-45. 20. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectinwithcoronaryheartdiseaseandmortality:theRanchoBernardo study. Am J Epidemiol 2007;165(2):164-74. Referências 352